A generic platform for the immobilisation of engineered biocatalysts

• 全文链接
• 请求原文

作   者：

Thompson, Matthew P.;  Derrington, Sasha R.;  Heath, Rachel S.;  Porter, Joanne L.;  Mangas-Sanchez, Juan;  Devine, Paul N.;  Truppo, Matthew D.;  Turner, Nicholas J.; 

作者机构：

Manchester Inst Biotechnol;  131 Princess St;  Sch Chem;  Univ Manchester;  Merck & Co Inc;  Rahway;  NJ 07065 USA;  England;  126 East Lincoln Ave;  Manchester M1 7DN;  Lancs; 

关键词：

Biocatalysis;  Immobilisation;  Controlled-pore glass;  Engineered enzymes; 

期刊名称：

Tetrahedron

i s s n：

0040-4020

年卷期：

2019 年 75 卷 3 期

页   码：

327-334

页   码：

摘   要：

The application of biocatalysis in the pharmaceutical industry is rapidly growing as a result of increased access to enzymes that meet the demands of industrial processes. This expansion of activity has led to a corresponding increase in the demand for immobilised enzymes. EziG (TM) (EnginZyme AB, Sweden) is marketed as a general matrix for enzyme immobilisation on controlled porosity glass. In this work we identified criteria for a "general" enzyme immobilisation technology in the context of the requirements of the pharmaceutical industry. We subsequently evaluated EziG (TM) for generality in a series of case studies for the application of immobilised biocatalysts. In this study we have focussed on the challenges facing both academic and industrial applications such as enzyme stability, multistep reactions and reactions in continuous flow. (C) 2018 Elsevier Ltd. All rights reserved.